Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Common-Size Balance Sheet: Assets
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Reportable Segments
- Dividend Discount Model (DDM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Analysis of Debt
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Solvency Ratios (Summary)
Abbott Laboratories, solvency ratios (quarterly data)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Debt to Equity Ratio
- The debt to equity ratio demonstrates a consistent downward trend from a high of 0.64 in the second quarter of 2020 to 0.27 by the second quarter of 2025. This steady decline indicates a progressive reduction in leverage, reflecting a stronger equity base relative to debt over time.
- Debt to Capital Ratio
- Similarly, the debt to capital ratio decreases gradually, moving from 0.39 in mid-2020 to 0.21 by mid-2025. The decreasing ratio signifies a lower proportion of debt within the company's overall capital structure, suggesting improved financial stability and reduced reliance on borrowed funds.
- Debt to Assets Ratio
- The debt to assets ratio follows a comparable downward pattern, declining from 0.29 in the second quarter of 2020 to 0.16 by the second quarter of 2025. This decline indicates a diminishing share of assets financed by debt, contributing to a more solid asset base and potentially reducing financial risk.
- Financial Leverage Ratio
- Financial leverage ratio exhibits a gradual reduction from 2.25 in the second quarter of 2020 to 1.66 by the second quarter of 2025. This decrease suggests a conservative approach to leveraging, with the company increasingly relying on equity to finance its assets instead of debt.
- Interest Coverage Ratio
- Interest coverage ratio shows an improving trend starting from 10.1 in the fourth quarter of 2020, peaking above 20 in mid-2022, and stabilizing between 11 and 16 in recent quarters. The rising coverage ratio reflects enhanced ability to meet interest obligations from operating earnings, indicating increasing operational profitability and reduced credit risk.
- Overall Summary
- Across all presented financial leverage metrics, there is a clear and consistent trend toward reduced indebtedness and enhanced financial robustness. The ratios illustrate a deliberate and sustained de-leveraging process, accompanied by stronger earnings performance enabling higher interest coverage. This pattern points to improved financial health, lower risk profile, and greater capacity for investment or debt servicing moving forward.
Debt Ratios
Coverage Ratios
Debt to Equity
Abbott Laboratories, debt to equity calculation (quarterly data)
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||||||
| Total Abbott shareholders’ investment | |||||||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||||||
| Debt to equity1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to equity = Total debt ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
- Over the observed period, total debt demonstrates a general downward trend, decreasing from US$18,272 million at the beginning of 2020 to US$13,437 million by mid-2025. While the debt fluctuated slightly in the initial years with minor increases and decreases, the overall movement is a gradual reduction. Notably, there is a marked decline in total debt starting from late 2022, continuing through to 2025. This signifies a strategic reduction in leverage over time.
- Total Abbott Shareholders’ Investment
- The shareholders’ investment consistently increased throughout the timeline, rising from US$30,218 million in early 2020 to US$50,565 million by mid-2025. The growth is steady with no significant declines, indicating expanding equity possibly driven by retained earnings, capital infusions, or appreciation of assets. A pronounced acceleration in equity growth can be observed starting around early 2024, suggesting increased shareholder value or capital strengthening efforts during this phase.
- Debt to Equity Ratio
- The debt to equity ratio exhibits a clear declining trend, starting at 0.60 in March 2020 and dropping to 0.27 by June 2025. This reflects a substantial decrease in financial leverage, implying improved balance sheet strength and reduced reliance on debt financing relative to equity. The steady reduction, particularly noticeable from 2022 onwards, aligns with the simultaneous decrease in total debt and growth in shareholders’ equity, reinforcing the narrative of enhanced financial stability and prudent capital management.
- Summary
- Overall, the data indicate a strong strategic focus on debt reduction and equity growth over the analyzed quarters. The company appears to be strengthening its financial position by lowering leverage and increasing its equity base. This improves its credit profile and may provide greater flexibility for future investments or resilience against economic fluctuations. The steady trends suggest consistent financial policies over the period, with particular emphasis on enhancing shareholder value and reducing financial risk.
Debt to Capital
Abbott Laboratories, debt to capital calculation (quarterly data)
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||||||
| Total Abbott shareholders’ investment | |||||||||||||||||||||||||||||
| Total capital | |||||||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||||||
| Debt to capital1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to capital = Total debt ÷ Total capital
= ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends regarding the company's debt and capital structure over the observed time periods.
- Total Debt
-
The total debt exhibited fluctuations initially, starting at approximately $18.3 billion in March 2020 and reaching a peak near $19.7 billion in June 2020 before generally trending downward. From early 2022 onwards, the total debt consistently declined, dropping from about $17.1 billion in March 2022 to roughly $13.4 billion by June 2025. This downward trend suggests active efforts in debt reduction over the latter periods.
- Total Capital
-
Total capital showed a moderate increase early in the timeline, moving from approximately $48.5 billion in March 2020 to slightly above $54 billion by the end of 2021. Thereafter, capital levels remained relatively stable with some incremental growth, surging from around $53 billion in early 2023 to over $64 billion by mid-2025. This indicates a strengthening capital base over the medium term.
- Debt to Capital Ratio
-
The debt to capital ratio demonstrated a clear declining trend throughout the entire period. Beginning at a level of 0.38 in the first quarter of 2020, the ratio gradually decreased, reaching approximately 0.31 by the end of 2022. Following this, it fell steadily to roughly 0.21 by mid-2025. This decline suggests improving financial leverage, with the firm relying less on debt relative to its capital base over time.
In summary, the company has significantly reduced its reliance on debt financing while maintaining and increasing its capital. The consistent decrease in the debt to capital ratio reinforces a stronger equity position, implying potentially lower financial risk and improved creditworthiness. The data reflects a strategic emphasis on debt management and capital structure optimization.
Debt to Assets
Abbott Laboratories, debt to assets calculation (quarterly data)
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Short-term borrowings | |||||||||||||||||||||||||||||
| Current portion of long-term debt | |||||||||||||||||||||||||||||
| Long-term debt, excluding current portion | |||||||||||||||||||||||||||||
| Total debt | |||||||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||||||
| Debt to assets1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Debt to assets = Total debt ÷ Total assets
= ÷ =
2 Click competitor name to see calculations.
- Total Debt
-
Total debt shows a general declining trend over the periods analyzed. Beginning at US$18,272 million in March 2020, the debt rose slightly in mid-2020, peaking at US$19,679 million in June 2020, before gradually decreasing. From the end of 2021 onward, there is a more consistent reduction in total debt, reaching US$13,437 million by June 2025. This decrease is indicative of effective debt management or repayment strategies over the four-year span.
- Total Assets
-
Total assets exhibit fluctuations within a relatively stable range from March 2020 through December 2023, varying between approximately US$66,777 million and US$75,196 million. Beginning in early 2024, assets show a marked upward trend, increasing sharply to US$81,448 million by June 2025. This rise suggests asset growth through acquisitions, capital investments, or appreciation of existing assets contributing to an overall strengthening of the asset base.
- Debt to Assets Ratio
-
The debt to assets ratio steadily decreases throughout the entire period, starting at 0.27 in March 2020 and falling to 0.16 by June 2025. This downward trend highlights improving financial leverage and lower reliance on debt financing relative to asset size. The ratio dropped more noticeably from late 2023 onward, aligning with the patterns of decreasing debt and increasing assets, indicating enhanced balance sheet strength and reduced financial risk.
Financial Leverage
Abbott Laboratories, financial leverage calculation (quarterly data)
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||||||
| Total Abbott shareholders’ investment | |||||||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||||||
| Financial leverage1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Financial leverage = Total assets ÷ Total Abbott shareholders’ investment
= ÷ =
2 Click competitor name to see calculations.
- Total Assets
- The total assets exhibit a generally upward trend from March 31, 2020, through June 30, 2025. Starting at approximately 66.8 billion US dollars in early 2020, the assets increase with fluctuations, peaking around 75.2 billion at the end of 2021. Following this period, there is a slight decline observed in 2022, with assets dropping to approximately 72.8 billion by September 30, 2022. After this dip, total assets resume growth again, reaching just under 84 billion by June 30, 2025. This pattern suggests consistent asset expansion over the five-year span, despite short-term volatility.
- Total Abbott Shareholders' Investment
- The shareholders' investment increases steadily over the analyzed period. Beginning at a bit over 30.2 billion dollars in March 2020, the investment grows incrementally with minor fluctuations until the end of 2024. Notable is a marked rise starting in early 2025, where the investment surges from approximately 39.8 billion at the end of 2024 to exceed 50.5 billion by June 30, 2025. This sharp increase might indicate equity infusions, retained earnings accumulation, or a combination thereof, reflecting strengthened equity backing.
- Financial Leverage
- Financial leverage demonstrates a clear declining trend throughout the period, moving from 2.21 in the first quarter of 2020 to 1.66 by the middle of 2025. This steady reduction signifies a decreasing reliance on debt relative to shareholders' equity. The leverage ratio falls consistently with no significant reversals, suggesting an improving capital structure and potentially lower financial risk over time.
- Overall Financial Position Summary
- The company shows a pattern of asset growth combined with a rising equity base and a decreasing financial leverage ratio. These trends collectively indicate strengthening financial robustness, with the business possibly enhancing its balance sheet quality by increasing equity while managing debt levels effectively. The sharp increase in shareholders' investment in 2025 stands out as a notable event, likely improving the company's capacity for risk absorption and future investments. The downward trend in leverage aligns with conservative financial management aimed at reducing debt dependence over the medium term.
Interest Coverage
Abbott Laboratories, interest coverage calculation (quarterly data)
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net earnings | |||||||||||||||||||||||||||||
| Less: Net earnings from discontinued operations, net of tax | |||||||||||||||||||||||||||||
| Add: Income tax expense | |||||||||||||||||||||||||||||
| Add: Interest expense | |||||||||||||||||||||||||||||
| Earnings before interest and tax (EBIT) | |||||||||||||||||||||||||||||
| Solvency Ratio | |||||||||||||||||||||||||||||
| Interest coverage1 | |||||||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | |||||||||||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Interest coverage
= (EBITQ2 2025
+ EBITQ1 2025
+ EBITQ4 2024
+ EBITQ3 2024)
÷ (Interest expenseQ2 2025
+ Interest expenseQ1 2025
+ Interest expenseQ4 2024
+ Interest expenseQ3 2024)
= ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Earnings before interest and tax (EBIT)
- The EBIT values exhibit considerable volatility throughout the observed periods. Starting at 772 million USD in the first quarter of 2020, EBIT declined to a low of 660 million USD in the subsequent quarter, followed by a strong recovery and peak at 2524 million USD in the last quarter of 2020. After peaking, EBIT fluctuated significantly, with a notable drop to 1474 million USD in the last quarter of 2022. From 2023 onwards, EBIT generally remained in a range from approximately 1577 to 2166 million USD, showing some recovery and moderate growth in several quarters. Nonetheless, the data indicate an absence of a stable upward or downward trend, with repeated fluctuations indicating variability in operating performance.
- Interest Expense
- Interest expense demonstrates relative stability with minor fluctuations over the observed time frame. The values consistently range from about 121 to 166 million USD. Early quarters show interest expenses near the higher end, around 139 to 136 million USD for 2020 and 135 to 131 million USD through 2021. Noticeable increases are seen in parts of 2022 and early 2023, with interest expenses peaking at approximately 166 million USD. Towards the end of the monitored period, interest expenses slightly decreased again to around 121 million USD by the last quarter of 2025. Overall, interest expense does not show a strong upward or downward trajectory but reveals some minor cyclical behavior.
- Interest Coverage Ratio
- The interest coverage ratio is only available from the third quarter of 2020, beginning at 10.1 and increasing steadily over time. The ratio reached a peak of approximately 20.07 by the second quarter of 2022. Subsequent quarters show a gradual decline to around 10.79 by the fourth quarter of 2023. Following this decline, there is a stable recovery and rising trend, with the ratio nearing 15.9 by the conclusion of the observed period in the second quarter of 2025. This pattern indicates an overall strengthening of the company’s ability to cover interest expenses from operating earnings over the long term, despite some intermediate variability.